UBS OCONNOR LLC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
UBS OCONNOR LLC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,366,665
+35.1%
121,153
+115.8%
0.04%
+9.4%
Q2 2023$1,011,877
+88.5%
56,153
+68.0%
0.03%
+100.0%
Q1 2023$536,741
-100.0%
33,421
-63.1%
0.02%
-52.9%
Q3 2022$1,777,000,000
+9.0%
90,460
+3.4%
0.03%
+41.7%
Q2 2022$1,631,000,00087,4600.02%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders